mobile-logo
 

All News

18 Oct

Conference Attendance Announcement – BioEurope 2023

by Peter Sargent
in Events
Comments

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, is pleased to announce that it is attending Europe’s Flagship Partnering Event for the Life Sciences Industry, BioEurope 2023 in Munich, Germany on November 6-8th.   Physiomics’ Chief Operating Officer, Dr Pete Sargent and Head of Business Development, Hayley Close will be attending the event. The aim is to engage with leaders from across...

Read More
18 Oct

Notice of AGM

by Charmaine Fraser
in Other News
Comments

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to provide notice of the Company’s Annual General Meeting (“AGM”).   The AGM will be held at 10.30 a.m. on 21 November 2023 at the Company’s new registered office, Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB.   Shareholders will shortly be sent...

Read More
17 Oct

News update from Physiomics October 2023

by Charmaine Fraser
in Blog
Comments

Leading mathematical modelling company, supporting oncology drug development. From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.   Top news Meet us at AACR-NCI-EORTC! Physiomics is attending the AACR-NCI-EORTC International Conference on Molecular Targets And Cancer Therapeutics at the Hynes Convention Center, Boston on...

Read More
04 Oct

Change of Registered Office

by Peter Sargent
in Investor News / RNS, Other News
Comments

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, announces that, effective today, its registered office has changed to Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB.   Enquiries: Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980   Hybridan LLP (Broker) Claire Louise Noyce +44 (0) 203 764 2341   Strand Hanson Ltd (NOMAD) James Dance & James Bellman +44 (0)20 7409 3494       Notes to Editor    About Physiomics Physiomics plc combines cutting...

Read More
03 Oct

Meet our new Chief Operating Officer, Dr Pete Sargent!

by Charmaine Fraser
in Blog
Comments

Pete joins us with experience working for a wide variety of life sciences businesses across R&D and commercial operations, read on to find out why he is excited to join Physiomics and where he sees the most potential!   Q: What attracted you to the role at Physiomics? A: “Having worked across the biopharma industry for many years, I’m acutely aware of the mounting pressures drug development companies...

Read More
03 Oct

Senior Management Announcement

by Jim Millen
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce the hiring this week of a new senior member of its team, Dr Venkata Putcha, as Head of Biostatistics.   Dr Putcha brings with him over 22 years of experience working within drug development, with over 17 years working for many...

Read More
20 Sep

Conference Attendance Announcement

by Charmaine Fraser
in Events
Comments

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, is pleased to announce that it is attending the AACR-NCI-EORTC International Conference on Molecular Targets And Cancer Therapeutics at the Hynes Convention Center, Boston on 11-15th October 2023.   Physiomics will be presenting a poster entitled “Preclinical pharmacokinetic (PK) and tumor growth inhibition (TGI) modeling for mANK-101, an anchored murine interleukin-12 (IL-12) complex for intratumoral...

Read More
11 Sep

News update from Physiomics September 2023

by Charmaine Fraser
in Blog
Comments

Leading mathematical modelling company, supporting oncology drug development. From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.   Top news   Exciting new contract with Numab! We are pleased to announce that we have been awarded a further contract by existing client, Numab Therapeutics. The project...

Read More
04 Sep

Senior Management Update

by Charmaine Fraser
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce the hiring of a new member of its senior management team.  Effective today, Dr Peter Sargent will be joining the Company as Chief Operating Officer ("COO").   Prior to joining us, Dr Sargent held a senior management role at global consultancy...

Read More